Primecap Management Co. CA Has $13.90 Million Position in WAVE Life Sciences Ltd. $WVE

Primecap Management Co. CA lessened its holdings in WAVE Life Sciences Ltd. (NASDAQ:WVE) by 23.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,898,650 shares of the company’s stock after selling 567,200 shares during the quarter. Primecap Management Co. CA’s holdings in WAVE Life Sciences were worth $13,898,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in WVE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of WAVE Life Sciences by 9.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,349 shares of the company’s stock valued at $463,000 after acquiring an additional 4,957 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in WAVE Life Sciences by 3.8% during the first quarter. Goldman Sachs Group Inc. now owns 557,644 shares of the company’s stock worth $4,506,000 after purchasing an additional 20,624 shares during the period. Teacher Retirement System of Texas boosted its holdings in WAVE Life Sciences by 8.2% during the second quarter. Teacher Retirement System of Texas now owns 28,955 shares of the company’s stock valued at $188,000 after purchasing an additional 2,206 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of WAVE Life Sciences by 93.3% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 36,097 shares of the company’s stock valued at $235,000 after purchasing an additional 17,424 shares during the period. Finally, Compass Rose Asset Management LP acquired a new position in shares of WAVE Life Sciences in the 2nd quarter worth approximately $650,000. 89.73% of the stock is owned by institutional investors.

WAVE Life Sciences Trading Down 9.3%

Shares of WVE stock opened at $13.93 on Friday. WAVE Life Sciences Ltd. has a 1 year low of $5.28 and a 1 year high of $21.73. The firm’s 50 day moving average is $14.45 and its 200-day moving average is $10.79. The firm has a market capitalization of $2.33 billion, a price-to-earnings ratio of -11.42 and a beta of -1.78.

WAVE Life Sciences (NASDAQ:WVE) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 140.75%. The company had revenue of $17.25 million during the quarter. On average, equities research analysts forecast that WAVE Life Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the company. Truist Financial boosted their price target on WAVE Life Sciences from $36.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, December 15th. HC Wainwright boosted their target price on shares of WAVE Life Sciences from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, December 19th. UBS Group set a $32.00 target price on shares of WAVE Life Sciences in a research report on Tuesday, December 16th. Citigroup lifted their price target on shares of WAVE Life Sciences from $16.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Finally, Morgan Stanley set a $28.00 price target on shares of WAVE Life Sciences in a research report on Monday, December 8th. Thirteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $33.00.

WAVE Life Sciences News Roundup

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: INHBE obesity program progressing — Wave is advancing WVE‑007 (INHBE GalNAc‑siRNA) and is positioning it as a once‑ or twice‑yearly obesity treatment; early data show fat loss at three months similar to GLP‑1s while preserving muscle, which if confirmed could be a high‑value, low‑frequency dosing differentiator. Wave Life Sciences targets once or twice yearly obesity treatment as INHBE program advances
• Positive Sentiment: On track for near‑term clinical readout — Company press release reiterates INLIGHT data update expected in 1Q 2026 and highlights durable fat‑loss signals and dose‑response expectations for WVE‑007, providing a clear upcoming catalyst. Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Q4 call and transcript show mixed messaging — Management walked through a revenue beat but flagged pressures and gave operational context on the pipeline; the call transcript and highlight pieces provide detail for modeling near‑term revenue and R&D cadence. Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Earnings miss and weak profitability metrics — WVE reported Q4 EPS of ($0.30), missing consensus by $0.02, though revenue of $17.25M topped expectations; the company still shows large negative margins and negative ROE, underscoring continued cash burn and dilution risk. Wave Life Sciences (WVE) Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: Insider sale by a senior executive — Chris Francis sold 33,194 shares (~$15.05 avg), cutting his ownership nearly 35%; while insider sales can be for personal reasons, markets often interpret sizable reductions by executives as a near‑term negative signal. Chris Francis insider sale

Insider Buying and Selling

In related news, CEO Paul Bolno sold 10,480 shares of WAVE Life Sciences stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $140,956.00. Following the completion of the sale, the chief executive officer directly owned 275,520 shares in the company, valued at $3,705,744. This trade represents a 3.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Chandra Vargeese sold 3,228 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $43,416.60. Following the sale, the insider directly owned 408,246 shares of the company’s stock, valued at $5,490,908.70. This represents a 0.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 948,375 shares of company stock worth $14,112,151. 23.98% of the stock is currently owned by company insiders.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.